Clinical trial

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

NCT02047734

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-12-03

PhasePHASE3

Study timeline

Study start (actual)2013-12-03Date precision: day

Registry last updated2021-02-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing Multiple Sclerosisunresolved

Interventions

OzanimodDRUG · verified · RxNorm: ozanimod

Ozanimod placeboDRUG

Interferon beta-1aDRUG · verified · RxNorm: interferon beta-1a

Interferon beta-1a placeboDRUG

Sponsors & collaborators

Celgenelead sponsor

Mapped research locations

SofiaBulgaria12 WarsawPoland10 BelgradeSerbia8 KatowicePoland8 AthensGreece7 ZagrebCroatia6 LondonUnited Kingdom4 PhoenixArizona, United States4 MoscowRussia4 BudapestHungary4 PoznanPoland4 LublinPoland4

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02047734 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.